Neonc Technologies Holdings Inc (NTHI) Stock Price, Quote & News

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 663 7831

Website: www.neonc.com

Address:

23975 Park Sorrento, Suite 205, Calabasas, United States

CEOBuysDisclosures Aug. 18 at 10:15 PM

$NTHI CEO purchased 36,259 shares at $3.86 for a total of $140,000. CHEN THOMAS C now owns 4,660,135 shares. https://ceo-buys.com

0 · Reply

CEOBuysDisclosures Aug. 18 at 8:40 PM

$NTHI CEO purchased 9,000 shares at $5.54 for a total of $49,860. Heshmatpour Amir F now owns 7,616,140 shares. https://ceo-buys.com

0 · Reply

AC_TRADER Aug. 18 at 6:51 PM

$NTHI key levels 👀 Mapped with @TrendSpider https://share.trendspider.com/chart/NTHI/7594z0q7zf

0 · Reply

Beroname Aug. 18 at 6:34 PM

$NTHI is BO possible on this stage?

0 · Reply

CEOBuysDisclosures Aug. 18 at 12:55 AM

$NTHI CEO purchased 15,000 shares at $3.90 for a total of $58,580. Heshmatpour Amir F now owns 7,607,140 shares. https://ceo-buys.com

0 · Reply

STACKD0E Aug. 17 at 5:38 PM

$NTHI 🙃 ✨️

0 · Reply

STACKD0E Aug. 17 at 5:37 PM

$NTHI $QNT 🙃✨️

0 · Reply

Hassan77 Aug. 17 at 4:27 PM

$NTHI Setting up here for a pump

0 · Reply

gobio Aug. 17 at 4:09 PM

$NTHI Something just happened. Partnership or Buyout???

0 · Reply

OhHappyDays Aug. 14 at 8:21 PM

$SLS Hey Y'all check out $NTHI they release some very positive data for their phase 2 yesterday. It is a low float ~2mil shares and no RS yet. However, just know they only have 2mil dollars left and will most likely need to raise more money. However, their data is very promising still. Here is a link from their readout https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-reports-positive-topline-phase-2a-results

3 · Reply

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't

Aug 17, 2026, 3:26 PM EDT - 1 day ago

These Nasdaq Stories Are Heating Up

Aug 17, 2026, 8:45 AM EDT - 1 day ago

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

2026-08-17T09:20:34.000Z - 2 days ago

NeOnc says Phase 2a portion of NEO100-01 study met primary endpoint

Aug 14, 2026, 1:00 PM EDT - 4 days ago

NeOnc Technologies Holdings Transcript: AGM 2026

Aug 13, 2026, 4:18 PM EDT - 5 days ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Aug 13, 2026, 2:31 PM EDT - 5 days ago

The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

Aug 12, 2026, 9:38 AM EDT - 6 days ago

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

Aug 12, 2026, 9:25 AM EDT - 6 days ago

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Aug 12, 2026, 8:30 AM EDT - 6 days ago

NeOnc Technologies Holdings Transcript: Study result

Aug 12, 2026, 8:30 AM EDT - 6 days ago

NeOnc Technologies Holdings Press release: Study result

Aug 12, 2026, 8:00 AM EDT - 6 days ago

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Aug 11, 2026, 8:44 AM EDT - 7 days ago

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

Aug 10, 2026, 9:00 AM EDT - 8 days ago

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

Aug 10, 2026, 8:30 AM EDT - 8 days ago

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Aug 10, 2026, 7:00 AM EDT - 8 days ago

NeOnc Technologies Holdings Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 8 days ago

NeOnc Technologies Holdings Earnings release: Q2 2026

Jul 27, 2026, 9:00 AM EDT - 22 days ago

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

Jul 15, 2026, 9:00 AM EDT - 4 weeks ago

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

Jul 1, 2026, 9:32 AM EDT - 6 weeks ago

Wall Street is Watching These Biotechs

ELAB

Jun 24, 2026, 8:45 AM EDT - 7 weeks ago

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

Jun 23, 2026, 9:00 AM EDT - 2 months ago

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

Jun 23, 2026, 8:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 23, 2026, 8:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 22, 2026, 8:45 AM EDT - 2 months ago

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

Jun 17, 2026, 9:18 AM EDT - 2 months ago

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Jun 16, 2026, 1:49 PM EDT - 2 months ago

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

Jun 16, 2026, 9:00 AM EDT - 2 months ago

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

2026-06-15T20:31:23.000Z - 2 months ago

NeOnc Technologies files to sell 555,554 shares of common stock for holders

Jun 15, 2026, 8:35 AM EDT - 2 months ago

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

Jun 15, 2026, 8:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

Jun 11, 2026, 8:00 AM EDT - 2 months ago

NeOnc Technologies Holdings Proxy statement: Proxy filing

Jun 9, 2026, 8:45 AM EDT - 2 months ago

The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade

May 29, 2026, 9:05 AM EDT - 2 months ago

The Next Great AI Revolution May Be Drug Delivery

May 19, 2026, 10:28 AM EDT - 3 months ago

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

2026-05-19T11:05:51.000Z - 3 months ago

NeOnc Technologies initiated with a Buy at Alliance Global

May 18, 2026, 9:00 AM EDT - 3 months ago

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

2026-05-18T12:00:00.000Z - 3 months ago

NeOnc Technologies initiated with a Buy at Maxim

May 18, 2026, 7:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 3 months ago

NeOnc Technologies Holdings Quarterly report: Q1 2026

May 7, 2026, 8:45 AM EDT - 3 months ago

Biotech's Next Wave May Already be in Motion

May 6, 2026, 8:35 AM EDT - 3 months ago

Where Executives Are Doubling Down on Their Companies' Fortunes

May 5, 2026, 9:00 AM EDT - 3 months ago

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

2026-04-24T10:17:12.000Z - 4 months ago

NeOnc Technologies initiated with a Buy at BTIG

2026-04-10T21:20:42.000Z - 4 months ago

NeOnc Technologies files to sell 680,558 shares of common stock for holders

Apr 10, 2026, 8:00 AM EDT - 4 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

2026-04-02T17:07:18.000Z - 4 months ago

NeOnc Technologies files $300M mixed securities shelf

Apr 2, 2026, 8:00 AM EDT - 4 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

Apr 1, 2026, 9:00 AM EDT - 4 months ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Apr 1, 2026, 7:00 AM EDT - 4 months ago

NeOnc Technologies Holdings Earnings release: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 4 months ago

NeOnc Technologies Holdings Annual report: Q4 2025

2026-03-13T13:05:36.000Z - 5 months ago

NeOnc Technologies appoints Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 5 months ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 12, 2026, 8:52 AM EDT - 5 months ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

2026-03-04T13:06:31.000Z - 5 months ago

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

Mar 4, 2026, 8:00 AM EST - 5 months ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

Feb 27, 2026, 9:00 AM EST - 6 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

2026-02-06T21:55:14.000Z - 6 months ago

NeOnc Technologies files to sell 2.95M shares of common stock for holders

Feb 6, 2026, 7:00 AM EST - 6 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

2026-01-30T14:17:11.000Z - 7 months ago

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

Jan 30, 2026, 9:00 AM EST - 7 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 9, 2026, 7:32 PM EST - 7 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

2025-12-15T14:16:09.000Z - 8 months ago

NeOnc Technologies announces updated NEO100 clinical results

Dec 15, 2025, 9:00 AM EST - 8 months ago

NeOnc Technologies Reports Updated Clinical Results

2025-12-15T13:00:48.000Z - 8 months ago

NeOnc Technologies files to sell 111.7K shares of common stock for holders

Dec 15, 2025, 7:00 AM EST - 8 months ago

NeOnc Technologies Holdings Registration statement: Registration filing

2025-12-01T14:10:42.000Z - 9 months ago

NeOnc Technologies announces preclinical findings from USC collaboration

Dec 1, 2025, 9:00 AM EST - 9 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Nov 14, 2025, 7:00 AM EST - 9 months ago

NeOnc Technologies Holdings Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

NeOnc Technologies Holdings Quarterly report: Q3 2025

2025-11-13T14:16:23.000Z - 9 months ago

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

Nov 13, 2025, 9:00 AM EST - 9 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

2025-11-12T13:26:29.000Z - 9 months ago

NeOnc announces updated results Phase 1/2a, compassionate care studies

Nov 7, 2025, 9:00 AM EST - 10 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

2025-11-04T14:05:59.000Z - 10 months ago

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

2025-10-28T13:10:14.000Z - 10 months ago

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

2025-10-09T13:10:30.000Z - 11 months ago

NeOnc Technologies’ NuroMENA signs master services agreement with M42’s IROS

Oct 9, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Sep 29, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 10, 2025, 9:40 AM EDT - 1 year ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

Sep 10, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Aug 25, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 19, 2025, 7:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Earnings release: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 1 year ago

NeOnc Technologies Holdings Quarterly report: Q2 2025

Aug 11, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 7, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 4, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Jul 30, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 23, 2025, 10:53 AM EDT - 1 year ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 8, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

CEOBuysDisclosures Aug. 18 at 10:15 PM

$NTHI CEO purchased 36,259 shares at $3.86 for a total of $140,000. CHEN THOMAS C now owns 4,660,135 shares. https://ceo-buys.com

0 · Reply

CEOBuysDisclosures Aug. 18 at 8:40 PM

$NTHI CEO purchased 9,000 shares at $5.54 for a total of $49,860. Heshmatpour Amir F now owns 7,616,140 shares. https://ceo-buys.com

0 · Reply

AC_TRADER Aug. 18 at 6:51 PM

$NTHI key levels 👀 Mapped with @TrendSpider https://share.trendspider.com/chart/NTHI/7594z0q7zf

0 · Reply

Beroname Aug. 18 at 6:34 PM

$NTHI is BO possible on this stage?

0 · Reply

CEOBuysDisclosures Aug. 18 at 12:55 AM

$NTHI CEO purchased 15,000 shares at $3.90 for a total of $58,580. Heshmatpour Amir F now owns 7,607,140 shares. https://ceo-buys.com

0 · Reply

STACKD0E Aug. 17 at 5:38 PM

$NTHI 🙃 ✨️

0 · Reply

STACKD0E Aug. 17 at 5:37 PM

$NTHI $QNT 🙃✨️

0 · Reply

Hassan77 Aug. 17 at 4:27 PM

$NTHI Setting up here for a pump

0 · Reply

gobio Aug. 17 at 4:09 PM

$NTHI Something just happened. Partnership or Buyout???

0 · Reply

OhHappyDays Aug. 14 at 8:21 PM

3 · Reply

topstockalerts Aug. 14 at 8:07 PM

$NTHI buyers seem very comfortable stepping in here

0 · Reply

NeOnc_Technologies Aug. 14 at 7:15 PM

$NVDA The latest PR reinforces that clinical development isn't defined by a single number—it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months. The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile. As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence—not a single readout. $NTHI $MRK $EXEL $CGON

0 · Reply

Tariqlati Aug. 14 at 3:45 PM

$NTHI pump and ?

2 · Reply

SRY2026 Aug. 14 at 2:49 PM

$XHG to $NTHI 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

alecsalaur198 Aug. 14 at 2:17 PM

$NTHI moving higher

0 · Reply

STACKD0E Aug. 14 at 2:16 PM

$NTHI $KOPN 👁️

0 · Reply

NeOnc_Technologies Aug. 13 at 9:52 PM

Clinical evidence doesn't stop on the day results are announced. Alongside a median overall survival of 26.1 months, five patients remain on NEO100, allowing the program to continue building long-term clinical evidence. $NTHI

0 · Reply

focafoca99 Aug. 13 at 8:40 PM

$NTHI underscores a strong 2Q26 readout as NEO100 hits 48.9% PFS-6 and median OS 26.1 months, boosting its registrational outlook.

0 · Reply

newsfile_corp Aug. 13 at 8:18 PM

https://nfne.ws/309582 $NTHI #InvestmentBanking #QuarterlyResults #NASDAQ #Investing

0 · Reply

NeOnc_Technologies Aug. 13 at 11:26 AM

The latest PR highlights more than clinical results; it reinforces the scientific rationale behind NEO100's development. One of the biggest challenges in brain cancer isn't identifying promising therapies, but delivering them across the blood-brain barrier to reach the tumor. NEO100 was specifically designed as an intranasal therapy to bypass that barrier, representing a different approach to drug delivery than conventional systemic administration. That strategy reflects NeOnc's focus on addressing one of the fundamental limitations in treating brain tumors. Innovation in brain cancer isn't only about discovering new molecules; it's also about finding better ways to deliver them where they're needed most. $NTHI $SMMT $CGON $MRK

0 · Reply

TNNStockAnalysisNews Aug. 13 at 5:53 AM

Top Stock Gainers Today — Aug 12, 2026 $BOXL — A Financial Runway Play Gains 60% $NOK — European Tech Strength Adds 9.7% $LITE — Optical Component Strength Continues, +7% $DFTX — Phase 3 Data Sparks a 20% Premarket Jump $NTHI — A Clinical Beat Drives Gains https://truthsandnews.com/markets/top-stock-gainers-today-aug-12-2026-ofal

0 · Reply

NeOnc_Technologies Aug. 12 at 8:00 PM

NEO100 met its primary endpoint, more than doubling the pre-specified benchmark for standard of care (48.9% vs. 20%). Results like these provide the clinical evidence development programs are designed to generate. $NTHI

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	9,700
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A